(Q38177909)

30 August 2017

0 references

Long-term macrolides for non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis (English)

1 reference

30 August 2017

0 references

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24417869%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

author name string

Weixing Shen

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24417869%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Haibo Cheng

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24417869%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Xiqiao Zhou

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24417869%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

language of work or name

1 reference

13 January 2014

1 reference

30 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24417869%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24417869%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24417869%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

page(s)

321-329

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24417869%20AND%20SRC:MED&resulttype=core&format=json

Quality-of-life determinants in patients with clinically stable bronchiectasis

31 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233

Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233

Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233

Mortality in bronchiectasis: a long-term study assessing the factors influencing survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233

Socioeconomic deprivation, readmissions, mortality and acute exacerbations of bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233

British Thoracic Society guideline for non-CF bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233

The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233

Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233

Long-term macrolide therapy in chronic inflammatory airway diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233

Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233

Macrolide antibiotics for cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233

Chronic macrolide therapy in inflammatory airways diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233

Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233

Prolonged antibiotics for purulent bronchiectasis in children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233

Macrolides and bronchiectasis: clinical benefit with a resistance price

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233

Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233

Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233

Users' guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233

Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233

Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233

Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233

Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233

A comparison of methods to detect publication bias in meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233

Exacerbations in noncystic fibrosis bronchiectasis: Clinical features and investigations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233

Quality of life and inflammation in exacerbations of bronchiectasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12233